MedTrace Logo

Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC)

NCT04222374 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-07-13

No results posted yet for this study

Summary

In the last decade, investigators from the Department of Cancer Epidemiology and Genetics (National Cancer Institute, USA) have conducted genome-wide association (GWAS) studies of renal cell carcinoma.

Dr. Mark PURDUE and Dr. Stephen CAHNOCK (Department of Epidemiology of Cancer and Genetics, NCI) propose to expand their genome-wide association study (Expanded GWAS) by genotyping approximately 10,000 additional cases of kidney cancer patients, in collaboration with US institutions, South-American and European.

This study describes the participation of the French Kidney Cancer Research Network (UroCCR) in the Expanded GWAS research, under the coordination of Professor BERNHARD (Bordeaux University Hospital).

Conditions

Interventions

PROCEDURE

Intervention in the UroCCR sites

1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent) 2. DNA extraction: * For the patients of Bordeaux University Hospital, 2 aliquots will be constituted: * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA, * 1 aliquot for the UroCCR biobank. * For patients from other UroCCR centers, only 1 aliquot will be constituted: * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA. 3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux.

PROCEDURE

Intervention in the CRB of Bordeaux University Hospital

1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank. 2. Overall packing of GWAS samples for shipment to the NCI. 3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study.

PROCEDURE

Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital

Transfer of the data associated with the samples to the NCI.

PROCEDURE

Subsequent intervention at the NCI (for information)

1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network. 2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University Hospital, Bordeaux

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2020-05-01
Completion
2020-05-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04222374 on ClinicalTrials.gov